Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 11 2024
0mins
Source: NASDAQ.COM
Overview of SPDR Russell 1000 Yield Focus ETF (ONEY): The SPDR Russell 1000 Yield Focus ETF, launched in 2015 and managed by State Street Global Advisors, focuses on large-cap value stocks with a low expense ratio of 0.20% and a 12-month trailing dividend yield of 3.08%. It has approximately $850.68 million in assets and aims to match the performance of the Russell 1000 Yield Focused Factor Index.
Performance and Comparison: As of October 2024, ONEY has gained about 12.89% year-to-date and 26.03% over the past year, with a diversified portfolio of around 293 holdings primarily in Consumer Staples. It is ranked as a "Hold" by Zacks, and investors may also consider similar ETFs like Schwab U.S. Dividend Equity ETF and Vanguard Value ETF for comparable exposure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MO
Wall Street analysts forecast MO stock price to fall
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 65.480
Low
57.00
Averages
65.00
High
72.00
Current: 65.480
Low
57.00
Averages
65.00
High
72.00
About MO
Altria Group, Inc. operates a portfolio of tobacco products for United States tobacco consumers aged 21+. Its segments include smokeable products and oral tobacco products. The smokeable products segment consists of combustible cigarettes and machine-made large cigars. The oral tobacco products segment includes moist smokeless tobacco (MST) products and oral nicotine pouches. Its wholly owned subsidiaries include manufacturers of both combustible and smoke-free products. In combustibles, it owns Philip Morris USA Inc. (PM USA), and John Middleton Co. (Middleton), which are cigarette manufacturers. Its smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), a global MST manufacturer, Helix Innovations LLC (Helix), a manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), an e-vapor manufacturer with a commercialized product portfolio. The brand portfolios of its operating companies include Marlboro, Black & Mild, Copenhagen, Skoal, on! and NJOY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altria Group's High-Yield Dividend and Cannabis Investment
- High-Yield Dividend: Altria Group offers a dividend yield exceeding 6%, providing investors with a steady cash flow, although its reliance on traditional cigarette sales remains high at 87%, indicating challenges in its transformation process.
- Cannabis Investment Status: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos, holding about 41% of its shares, yet this investment is currently valued at only $429 million, reflecting market caution towards the cannabis industry.
- Revenue Trends: While Altria's annual revenue consistently exceeds $20 billion, its net revenue after excise taxes has declined annually since 2021, dropping from $21.1 billion to $20.1 billion, highlighting the long-term decline in the traditional cigarette market.
- Future Strategy: Altria launched its
See More
Altria: A High-Yield Investment in Tobacco Amid Cannabis Interest
- Strong Profitability: Altria Group generates over $20 billion in annual revenue, maintaining a high net margin of 75.86% despite the long-term decline in cigarette consumption, showcasing robust financial resilience in a competitive market.
- Dividend King Status: With a 56-year streak of increasing dividends and a current yield of 6.39%, Altria remains a favorite among investors, particularly those seeking high-yield opportunities, further solidifying its market position.
- Strategic Transformation: The company has launched its 'Moving Beyond Smoking' strategy, aiming to double revenue from next-generation tobacco products to $5 billion by 2028; despite regulatory challenges and competitive pressures, this transformation indicates a forward-looking approach to future markets.
- Investment in Cannabis Market: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos in 2019, holding a 41% stake; although its current value is only $429 million, the potential for significant returns increases as marijuana legalization progresses.
See More
FDA Fast-Track Approval Program Faces Resistance
- FDA Review Delays: According to a Reuters report, the FDA is hesitant to approve certain nicotine pouch products, which could lead to delays in the fast-track approval program, posing potential risks for the entire tobacco industry.
- Altria's Stock Decline: While Altria (NYSE: MO) was less affected than other tobacco stocks during the sell-off, its share price still fell nearly 1% on Wednesday, reflecting market uncertainty regarding the future of tobacco products.
- Strong Market Reaction: Investors eagerly sold off tobacco stocks due to concerns over the FDA review, and although Altria's on! PLUS line has received fast-track approval, overall market sentiment remains bleak.
- Uncertain Industry Outlook: The Reuters report suggests that regulatory attitudes towards tobacco products may become more conservative, presenting challenges for tobacco companies, including Altria, in their future market performance.
See More
Altria Stock Declines Amid Regulatory Concerns Over Fast-Track Approval
- Stock Fluctuation: Altria (MO) shares fell nearly 1% on Wednesday, although the impact was less severe compared to other tobacco companies, primarily due to market concerns over potential delays in the fast-track approval program for certain products.
- Regulatory Slowdown: The U.S. Food and Drug Administration (FDA) may be slowing down the approval process for nicotine pouch products, leading to decreased investor confidence in tobacco stocks, especially for products still awaiting approval.
- Product Advantage: Altria's on! PLUS line is among the first nicotine pouch products to receive fast-track approval, providing a competitive edge in the market despite the overall negative sentiment.
- Market Outlook: Although Altria has recently benefited from regulatory approval, a continued cautious stance from the FDA regarding other tobacco products could pose challenges for future growth across the entire industry.
See More
FDA's Fast-Track Nicotine Pouch Approval Faces Resistance
- Resistance to Approval: The FDA's fast-track nicotine pouch approval plan is facing resistance from regulators and external critics due to insufficient scientific evidence, particularly concerns about addiction risks among youth, complicating the advancement of the initiative.
- Unclear Scientific Evidence: Although the FDA launched the pilot under pressure, it has not fully resolved the evidence balance between public health benefits for adult smokers and youth addiction risks, resulting in a slow approval process.
- Market Growth Potential: Nicotine pouches represent the fastest-growing tobacco category in the U.S., driving companies to seek quicker authorizations; however, advocacy groups warn that easier access could increase nicotine use among teenagers.
- Industry Participants: The FDA pilot aims to fast-track products from multiple companies, including Philip Morris, Altria, British American Tobacco's Reynolds American, and Turning Point Brands, highlighting the industry's urgent demand for rapid market access.
See More
Altria Stock Attracts Investors Back to Value
- Stock Price Surge: As of March 26, Altria (MO) has risen over 12% year-to-date, indicating investor preference for value stocks despite a sluggish overall market performance.
- Attractive Dividends: With a dividend yield of 6.5%, Altria has consistently increased its dividends for 57 consecutive years, earning it the title of 'Dividend King' and providing a competitive edge within the S&P 500.
- Market Challenges: While Altria leads the tobacco industry, the declining number of adult smokers in the U.S. poses a significant challenge; although the company has raised prices to offset volume declines, the long-term viability of this strategy is questionable.
- Investment Potential: Despite limited success in the smoke-free category, Altria's strong cash flow and ongoing shareholder return strategies, including a $1 billion stock buyback in 2025, continue to make it appealing to value investors.
See More
Altria Group's High-Yield Dividend and Cannabis Investment
- High-Yield Dividend: Altria Group offers a dividend yield exceeding 6%, providing investors with a steady cash flow, although its reliance on traditional cigarette sales remains high at 87%, indicating challenges in its transformation process.
- Cannabis Investment Status: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos, holding about 41% of its shares, yet this investment is currently valued at only $429 million, reflecting market caution towards the cannabis industry.
- Revenue Trends: While Altria's annual revenue consistently exceeds $20 billion, its net revenue after excise taxes has declined annually since 2021, dropping from $21.1 billion to $20.1 billion, highlighting the long-term decline in the traditional cigarette market.
- Future Strategy: Altria launched its
See More
Altria: A High-Yield Investment in Tobacco Amid Cannabis Interest
- Strong Profitability: Altria Group generates over $20 billion in annual revenue, maintaining a high net margin of 75.86% despite the long-term decline in cigarette consumption, showcasing robust financial resilience in a competitive market.
- Dividend King Status: With a 56-year streak of increasing dividends and a current yield of 6.39%, Altria remains a favorite among investors, particularly those seeking high-yield opportunities, further solidifying its market position.
- Strategic Transformation: The company has launched its 'Moving Beyond Smoking' strategy, aiming to double revenue from next-generation tobacco products to $5 billion by 2028; despite regulatory challenges and competitive pressures, this transformation indicates a forward-looking approach to future markets.
- Investment in Cannabis Market: Altria invested approximately $1.8 billion in Canadian cannabis company Cronos in 2019, holding a 41% stake; although its current value is only $429 million, the potential for significant returns increases as marijuana legalization progresses.
See More
FDA Fast-Track Approval Program Faces Resistance
- FDA Review Delays: According to a Reuters report, the FDA is hesitant to approve certain nicotine pouch products, which could lead to delays in the fast-track approval program, posing potential risks for the entire tobacco industry.
- Altria's Stock Decline: While Altria (NYSE: MO) was less affected than other tobacco stocks during the sell-off, its share price still fell nearly 1% on Wednesday, reflecting market uncertainty regarding the future of tobacco products.
- Strong Market Reaction: Investors eagerly sold off tobacco stocks due to concerns over the FDA review, and although Altria's on! PLUS line has received fast-track approval, overall market sentiment remains bleak.
- Uncertain Industry Outlook: The Reuters report suggests that regulatory attitudes towards tobacco products may become more conservative, presenting challenges for tobacco companies, including Altria, in their future market performance.
See More
Altria Stock Declines Amid Regulatory Concerns Over Fast-Track Approval
- Stock Fluctuation: Altria (MO) shares fell nearly 1% on Wednesday, although the impact was less severe compared to other tobacco companies, primarily due to market concerns over potential delays in the fast-track approval program for certain products.
- Regulatory Slowdown: The U.S. Food and Drug Administration (FDA) may be slowing down the approval process for nicotine pouch products, leading to decreased investor confidence in tobacco stocks, especially for products still awaiting approval.
- Product Advantage: Altria's on! PLUS line is among the first nicotine pouch products to receive fast-track approval, providing a competitive edge in the market despite the overall negative sentiment.
- Market Outlook: Although Altria has recently benefited from regulatory approval, a continued cautious stance from the FDA regarding other tobacco products could pose challenges for future growth across the entire industry.
See More
FDA's Fast-Track Nicotine Pouch Approval Faces Resistance
- Resistance to Approval: The FDA's fast-track nicotine pouch approval plan is facing resistance from regulators and external critics due to insufficient scientific evidence, particularly concerns about addiction risks among youth, complicating the advancement of the initiative.
- Unclear Scientific Evidence: Although the FDA launched the pilot under pressure, it has not fully resolved the evidence balance between public health benefits for adult smokers and youth addiction risks, resulting in a slow approval process.
- Market Growth Potential: Nicotine pouches represent the fastest-growing tobacco category in the U.S., driving companies to seek quicker authorizations; however, advocacy groups warn that easier access could increase nicotine use among teenagers.
- Industry Participants: The FDA pilot aims to fast-track products from multiple companies, including Philip Morris, Altria, British American Tobacco's Reynolds American, and Turning Point Brands, highlighting the industry's urgent demand for rapid market access.
See More
Altria Stock Attracts Investors Back to Value
- Stock Price Surge: As of March 26, Altria (MO) has risen over 12% year-to-date, indicating investor preference for value stocks despite a sluggish overall market performance.
- Attractive Dividends: With a dividend yield of 6.5%, Altria has consistently increased its dividends for 57 consecutive years, earning it the title of 'Dividend King' and providing a competitive edge within the S&P 500.
- Market Challenges: While Altria leads the tobacco industry, the declining number of adult smokers in the U.S. poses a significant challenge; although the company has raised prices to offset volume declines, the long-term viability of this strategy is questionable.
- Investment Potential: Despite limited success in the smoke-free category, Altria's strong cash flow and ongoing shareholder return strategies, including a $1 billion stock buyback in 2025, continue to make it appealing to value investors.
See More
